ArticleAntimicrobial agents and chemotherapy2010
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The spread of carbapenemase-producing bacteria in Africa: a systematic review.The Journal of antimicrobial chemotherapy · 2015Pooled it
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Epidemiological and genetic characteristics of clinical carbapenemase-producing Enterobacterales isolates from Batna hospitals in Algeria.BMC infectious diseases · 2024Article
- Clinical and Drug Resistance Characteristics ofMicroorganisms · 2024Article
- Emergence of Carbapenem-resistant Clinical Isolates ofJuntendo Iji zasshi = Juntendo medical journal · 2022Review
- Emergence of Carbapenem-Resistant Providencia rettgeri andAntimicrobial agents and chemotherapy · 2020Article
- Distribution of NDM1 Carbapenemase-ProducingInfection and drug resistance · 2020Article
- First literature review of carbapenem-resistantNew microbes and new infections · 2018Review
- Presence of VIM-Positive Pseudomonas Species in Chickens and Their Surrounding Environment.Antimicrobial agents and chemotherapy · 2017Article
- Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa.BMC infectious diseases · 2016Article
- Epidemiology of Carbapenem Resistant Klebsiella pneumoniae Infections in Mediterranean Countries.Mediterranean journal of hematology and infectious diseases · 2016Review
- Clinical and microbiological features of Providencia bacteremia: experience at a tertiary care hospital.The Korean journal of internal medicine · 2015Article
- Emergence of KPC-producing Klebsiella pneumoniae ST512 isolated from cerebrospinal fluid of a child in Algeria.New microbes and new infections · 2015Article
- First description of OXA-48-producing Escherichia coli and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
- NDM-5 carbapenemase-encoding gene in multidrug-resistant clinical isolates of Escherichia coli from Algeria.Antimicrobial agents and chemotherapy · 2014Article
- Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries.BioMed research international · 2014Review
- In-roads to the spread of antibiotic resistance: regional patterns of microbial transmission in northern coastal Ecuador.Journal of the Royal Society, Interface · 2012Article
- Characterization of metallo-beta-lactamase VIM-27, an A57S mutant of VIM-1 associated with Klebsiella pneumoniae ST147.Antimicrobial agents and chemotherapy · 2011Article
- Novel VIM metallo-beta-lactamase variant, VIM-24, from a Klebsiella pneumoniae isolate from Colombia.Antimicrobial agents and chemotherapy · 2011Article
- Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five different strains of bacteria belonging to the family Enterobacteriaceae were isolated from two patients hospitalized in the intensive care unit of the Central Military Hospital of Algiers, Algeria. All five strains, one Providencia stuartii strain, two Escherichia coli strains, and two Klebsiella pneumoniae strains, were intermediate or resistant to all beta-lactams, including carbapenems. Synergy between imipenem and EDTA was observed for all five strains. The results of the PCR experiment confirmed the presence of a bla(VIM) gene in all five strains. The bla(VIM) genes were located as part of a class 1 integron on a 180-kb conjugative plasmid. They encoded a novel metallo-beta-lactamase designated VIM-19, which differed from the parental enzyme VIM-1 by only two substitutions: Ser228Arg, previously observed in the closely related enzyme VIM-4, and Asn215Lys, not previously observed in other VIM-type carbapenemases. VIM-19 was further characterized after purification through determination of its kinetic constants. This enzyme was inhibited by EDTA and hydrolyzed penicillins, cephalosporins, and carbapenems, as observed for other VIM-type carbapenemases but with greater catalytic efficiency against penicillins than VIM-1. VIM-19 is the first carbapenemase enzyme identified from an isolate from Algeria. These results confirm the emergence of VIM-4-like enzymes in members of the family Enterobacteriaceae from Mediterranean countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.